Funded PhD studentship opportunity: Unlocking insights into skin cancer risk with laser-enabled skin analytics

Laser ablation of skin

We are pleased to announce a funded PhD studentship opportunity at Newcastle University, as part of the MRC DiMeN-XL doctoral programme.

The project, titled Unlocking insights into skin cancer risk with laser-enabled skin analytics, will investigate an innovative approach to skin analysis using medical laser technology, molecular biology, proteomics and advanced imaging.

The research will explore how ablative fractional lasers can be used for minimally invasive skin sampling to investigate molecular markers associated with photoageing, DNA damage and skin carcinogenesis. The ultimate aim is to improve our understanding of skin cancer risk and inform future approaches to skin cancer prevention.

The successful candidate will join our research group and work with an interdisciplinary supervisory team spanning biomedical technology, molecular dermatology, skin cancer biology and proteomics. The studentship also includes a three-month industrial placement with Lynton Lasers, offering valuable experience in medical laser technology and its clinical applications.

Interested?

The studentship is funded for four years. For full project details, eligibility requirements and application instructions, please visit the PhD studentship advert on FindAPhD.

We look forward to hearing from prospective applicants!

Doaa successfully defends her PhD thesis

Congratulations to Doaa on successfully defending her PhD thesis on the development of a microneedle platform for detecting malaria and dengue infections!

An emotional moment as Doaa celebrates her successful viva, with tears of joy! A wonderful culmination of years of hard work, dedication and research.

Many thanks to Dr Zeeshan Ahmad and Dr Jake McClements for examining the thesis, and to Professor Moein Moghimi for chairing the viva.

A fantastic achievement, Doaa. Well done!

APS PharmSci International Conference comes to Newcastle

This year’s APS PharmSci International Conference took place in Gateshead, near Newcastle, from 7–9 September 2026. Wing and I were delighted to work with the conference committee to bring the conference to the North East, having proposed Newcastle as this year’s host location.

Keng chaired the skin session, while Katarina delivered an invited talk on our ULTRA microneedles.

It was a pleasure to work alongside the conference committee in making the event happen and to meet so many speakers, delegates, exhibitors and students. The conference provided a fantastic opportunity to share our work, exchange ideas and connect with colleagues across the pharmaceutical sciences community.

More coverage in our LinkedIn posts:

Keng shares the story behind vac-and-fill, ULTRA and Otto in video podcast

“Our formulation broke the method.”

Over the last two years, our lab has developed three pharmaceutical technologies. At first glance, they might seem unrelated. But they all share a rather unexpected origin.

In this video podcast, Keng speaks with Dr Manveer Sandhu about how it all began with a single research challenge: developing a long-acting microneedle formulation.

The work required laboratory equipment that wasn’t readily available, so we decided to build our own. That decision set in motion a series of developments that eventually led to the three technologies we have today.

Watch the conversation below to discover how one research challenge led to three different pharmaceutical technologies.

Many thanks to Manveer for inviting us to share our story on his Signal over Noise podcast series.

Want to learn more? Visit our Publications section to explore the scientific papers behind these technologies.

Otto spotlighted in a HardwareX podcast interview

Our work on Otto, the Franz diffusion cell autosampler, has been spotlighted by the HardwareX journal in a recent podcast interview, Building OTTO: What an open source 3D printer is doing for drug research.

Liam Archbold and I were invited to talk through the project, covering both the technical design and the backstory, particularly our motivation to show that useful lab automation can be built using low‑cost, open, and modifiable hardware rather than proprietary systems.

It’s been encouraging to see a very practical piece of open hardware work developed at School of Pharmacy Newcastle University reach a wider audience. I hope that it will prompt others to adapt, reuse, or rethink how lab tools are designed, shared, and validated.

A very special shoutout to Hayley Chan and Wing Man Lau for their contributions to Otto. Thank you EPSRC and Newcastle University for funding, and thanks to everyone who has supported us along the way to make the project a success.

Learn more about Otto:

Transdermal delivery and formulation design of opioids: Where are we now and where are we heading?

Graphical Abstract

We have a new review article published in the Journal of Controlled Release: https://doi.org/10.1016/j.jconrel.2026.114894


Liang YM, Azizi J, Ng KW, Goh CF. Transdermal delivery and formulation design of opioids: Where are we now and where are we heading? J Control Release. 2026;394:114894. https://doi.org/10.1016/j.jconrel.2026.114894


This has been another excellent transnational collaboration with Dr Choon Fu Goh and colleagues. In this paper, we take a deep dive into a seemingly simple question with a deceptively complex answer: why is it so difficult to deliver opioid drugs across the skin?

Transdermal delivery offers clear advantages for opioid therapy, including more stable drug levels and improved patient convenience compared to oral or injectable routes. However, only a small number of opioids, such as fentanyl and buprenorphine, have been successfully developed into marketable patches. The main limitation is the skin itself. As a barrier, it is highly effective, and drugs require a very specific balance of properties, including molecular size, lipophilicity, and potency, to cross it. Many widely used opioids, including morphine, fall outside this narrow window.

In the review, we examine the main strategies that have been explored to address this challenge, including chemical permeation enhancers, formulation approaches, and physical methods. A consistent theme is that success in controlled laboratory settings does not always translate into clinical use. Improving permeation alone is not sufficient if the system cannot deliver clinically relevant doses reliably in practice. It increasingly appears that formulation strategies relying on passive diffusion across intact skin are unlikely to succeed. Looking ahead, active skin penetration strategies are likely to lead progress by enabling more consistent drug delivery while reducing dosing burden.

I thank my co-authors for their contributions to this work, and I hope the review will serve as a useful resource for the research community.

Welcome to the team, Anas!

We are delighted to welcome Anas Al-Masri to our research team as a PhD student.

Anas holds a BSc in Pharmacy from Syrian Private University and an MSc in Transfusion and Transplantation Sciences from the University of Bristol. He has a particular interest in innovative drug delivery systems and translational pharmaceutical technologies.

His PhD research will focus on developing long-acting ULTRA microneedles for the delivery of biologic drugs, particularly GLP-1 agonists. He will work closely with his supervisory team: Professor Katarina Novakovic, Dr Wing Man Lau and Dr Tarek Abdelghany.

Welcome to the team, Anas! We look forward to working with you.

January lab social

We went out for a meal with some current and former lab members. It was great to catch up over some lovely food and drink, and learn that everyone was doing well. We missed a few people who couldn’t join us, but we’ll surely keep in touch!

New paper shows how to build Otto

Ng KW, Archbold L, Lau WM. Building Otto: An open-source Franz diffusion cell autosampler for automating in vitro skin permeation studies. HardwareX. 2026;25:e00735. doi: 10.1016/j.ohx.2025.e00735


We have recently published a paper in HardwareX describing the design and construction of Otto, an open-source autosampler robot for Franz diffusion cell experiments. Otto is built using a desktop 3D printer as a gantry, a small number of custom 3D-printed parts, and commonly available laboratory consumables. It is designed to automate sampling and can collect up to 100 samples per run.

The system uses a Creality Ender 3 Pro 3D printer for motion control, with add-on components printed in-house on Prusa Research printers. The aim of the project was to develop a low-cost, accessible solution for automating repetitive sampling tasks in skin permeation studies, without reliance on proprietary hardware.

Otto has previously been validated. In a recent hydrogel study, Otto was used to collect every sample in a 72-hour skin permeation experiment, operating fully unattended throughout. The new HardwareX paper brings together the design rationale, build instructions and practical considerations needed for others to construct and use the system.

The paper, which is now available, provides a step-by-step guide to building Otto and is intended to support reproducibility and reuse by other laboratories. The 3D models and design files are openly available, and the models are also hosted on Printables.

Alongside the hardware, a companion application called OttoMate has been developed to generate the G-code used to control the system via a graphical user interface. The software is under active development and is available on GitHub.

A series of videos demonstrating different aspects of Otto’s operation, including assembly and sampling, is also available via a YouTube playlist.

This work was carried out by our team at Newcastle University, with contributions from Liam Archbold and Dr Wing Man Lau. Otto has been open-sourced in the hope that others will find it useful and adapt it for their own applications, and we are open to collaborations.

We would also like to acknowledge the EPSRC for funding this work.